Division of Hard Tissue Research, Institute for Oral Science, School of Dentistry, Matsumoto Dental University, Nagano 399-0781, Japan.
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):10006-11. doi: 10.1073/pnas.1207361109. Epub 2012 Jun 5.
Osteoclasts are generated from monocyte/macrophage-lineage precursors in response to colony-stimulating factor 1 (CSF-1) and receptor activator of nuclear factor-κB ligand (RANKL). CSF-1-mutated CSF-1(op/op) mice as well as RANKL(-/-) mice exhibit osteopetrosis (OP) caused by osteoclast deficiency. We previously identified RANKL receptor (RANK)/CSF-1 receptor (CSF-1R) double-positive cells as osteoclast precursors (OCPs), which existed in bone in RANKL(-/-) mice. Here we show that OCPs do not exist in bone but in spleen in CSF-1(op/op) mice, and spleen acts as their reservoir. IL-34, a newly discovered CSF-1R ligand, was highly expressed in vascular endothelial cells in spleen in CSF-1(op/op) mice. Vascular endothelial cells in bone also expressed IL-34, but its expression level was much lower than in spleen, suggesting a role of IL-34 in the splenic generation of OCPs. Splenectomy (SPX) blocked CSF-1-induced osteoclastogenesis in CSF-1(op/op) mice. Osteoclasts appeared in aged CSF-1(op/op) mice with up-regulation of IL-34 expression in spleen and bone. Splenectomy blocked the age-associated appearance of osteoclasts. The injection of 2-methylene-19-nor-(20S)-1α,25(OH)(2)D(3) (2MD), a potent analog of 1α,25-dihidroxyvitamin D(3), into CSF-1(op/op) mice induced both hypercalcemia and osteoclastogenesis. Administration of 2MD enhanced IL-34 expression not only in spleen but also in bone through a vitamin D receptor-mediated mechanism. Either splenectomy or siRNA-mediated knockdown of IL-34 suppressed 2MD-induced osteoclastogenesis. These results suggest that IL-34 plays a pivotal role in maintaining the splenic reservoir of OCPs, which are transferred to bone in response to diverse stimuli, in CSF-1(op/op) mice. The present study also suggests that the IL-34 gene in vascular endothelial cells is a unique target of vitamin D.
破骨细胞由单核细胞/巨噬细胞前体在集落刺激因子 1(CSF-1)和核因子-κB 配体受体激活剂(RANKL)的刺激下产生。CSF-1 突变 CSF-1(op/op) 小鼠和 RANKL(-/-) 小鼠表现出破骨细胞缺乏引起的骨质增生(OP)。我们之前鉴定了 RANKL 受体(RANK)/CSF-1 受体(CSF-1R)双阳性细胞作为破骨细胞前体(OCPs),其存在于 RANKL(-/-) 小鼠的骨骼中。在这里,我们表明 OCPs 不存在于骨骼中,而是存在于 CSF-1(op/op) 小鼠的脾脏中,脾脏是它们的储备库。白细胞介素 34(IL-34)是一种新发现的 CSF-1R 配体,在 CSF-1(op/op) 小鼠的脾脏血管内皮细胞中高度表达。骨中的血管内皮细胞也表达 IL-34,但表达水平要低得多,这表明 IL-34 在脾脏中 OCPs 的生成中起作用。脾切除术(SPX)阻断了 CSF-1(op/op) 小鼠中 CSF-1 诱导的破骨细胞生成。随着 IL-34 在脾脏和骨骼中的表达上调,老年 CSF-1(op/op) 小鼠中出现了破骨细胞。脾切除术阻断了与年龄相关的破骨细胞出现。2-亚甲基-19-降-(20S)-1α,25(OH)(2)D(3)(2MD)的注射,一种 1α,25-二羟维生素 D(3)的有效类似物,进入 CSF-1(op/op) 小鼠体内会引起高钙血症和破骨细胞生成。2MD 的给药不仅通过维生素 D 受体介导的机制增强了脾脏中的 IL-34 表达,而且还增强了骨骼中的表达。脾切除术或 IL-34 的 siRNA 介导的敲低抑制了 2MD 诱导的破骨细胞生成。这些结果表明,IL-34 在 CSF-1(op/op) 小鼠中维持 OCPs 的脾脏储备中发挥关键作用,这些细胞在各种刺激下转移到骨骼中。本研究还表明,血管内皮细胞中的 IL-34 基因是维生素 D 的独特靶标。